References

1. Ben-Eliyahu, S., Marek, P., Vaccarino, A. L., Mogil, J. S., Sternberg, W. F., and Liebeskind, J. C. (1992) The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat. Brain Res. 575, 304-308.

2. Trujillo, K. A. and Akil, H. (1991) Inhibition of morphine tolerance and dependence by the NMDA receptor anagonist MK-801. Science 251, 85-87.

3. Gutstein, H. B. and Trujillo, K. A. (1993) MK-801 inhibits the development of morphine tolerance at spinal sites. Brain Res. 626, 332-334.

4. Kolesnikov, Y. A., Maccechini, M.-L., and Pasternak, G. W. (1994) 1-Aminocyclopropane carboxylic acid (ACPC) prevents mu and delta opioid tolerance. Life Sci. 55, 1393-1398.

5. Kolesnikov, Y. A., Ferkany, J., and Pasternak, G. W. (1993) Blockade of mu and kappa1 opioid analgesic tolerance by NPC17742, a novel NMDA antagonist. Life Sci. 53, 1489-1494.

6. Tiseo, P. and Inturrisi, C. E. (1993) Attenuation and reversal of morphine tolerance by the competitive N-methyl-d-aspartate antagonist LY274614. J. Pharmacol. Exp. Ther. 264, 1090-1096.

7. Bhargava, H. N. and Thorat, S. N. (1994) Effect of dizocilpine (MK-801) on analgesia and tolerance induced by U-50,488H, a kappa-opioid receptor agonist, in the mouse. Brain Res. 649, 111-116.

8. Elliott, K., Minami, N., Kolesnikov, Y. A., Pasternak, G. W., and Inturrisi, C. E. (1994) The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-l-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain 56, 69-75.

9. Pasternak, G. W. and Inturrisi, C. (1995) Pharmacological modulation of opioid tolerance. Exp. Opin. Invest. Drugs 4, 271-281.

10. Pasternak, G. W., Kolesnikov, Y. A., and Babey, A. M. (1995) Perspectives on the N-methyl-d-aspartate nitric oxide cascade and opioid tolerance. Neuropsychopharmacology 13, 309-313.

11. Kolesnikov, Y., Jain, S., and Pasternak, G. W. (1996) Modulation of opioid analgesia by agmatine. Eur. J. Pharmacol. 296, 17-22.

12. Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S., and Snyder, S. H. (1991) Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl. Acad. Sci. USA 88, 6368-6371.

13. Dawson, V. L., Dawson, T. M., Bartley, D. A., Uhl, G. R., and Snyder, S. H. (1993) Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J. Neurosci. 13, 2651-2661.

14. Kolesnikov, Y. A., Pick, C. G., Ciszewska, G., and Pasternak, G. W. (1993) Blockade of tolerance to morphine but not to kappa opioids by a nitric oxide synthase inhibitor. Proc. Natl. Acad. Sci. USA 90, 5162-5166.

15. Babey, A. M., Kolesnikov, Y., Cheng, J., Inturrisi, C. E., Trifilletti, R. R., and Pasternak, G. W. (1994) Nitric oxide and opioid tolerance. Neuropharmacology 33, 1463-1470.

16. Bohn, L. M., Gainetdinov, R. R., Lin, F. T., Lefkowitz, R. J., and Caron, M. G. (2000) Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408, 720-723.

17. Aley, K. O. and Levine, J. D. (1997) Dissociation of tolerance and dependence for opioid peripheral antinociception in rats. J. Neurosci. 17, 3907-3912.

18. London, E. D., Vaupel, D. B., and Kimes, A. S. (1994) Inhibitors of nitric oxide synthase as potential treatments for opioid withdrawal. Regul. Pept. 54, 165-166.

19. Bhargava, H. N. (1995) Attenuation of tolerance to, and physical dependence on, morphine in the rat by inhibition of nitric oxide synthase. Gen. Pharmacol. 26, 1049-1053.

20. Kolesnikov, Y. A., Pan, Y. X., Babey, A. M., Jain, S., Wilson, R., and Pasternak, G. W. (1997) Functionally differentiating two neuronal nitric oxide synthase isoforms through antisense mapping: Evidence for opposing NO actions on morphine analgesia and tolerance. Proc. Natl. Acad. Sci. USA 94, 8220-8225.

21. Brenman, J. E., Chao, D. S., Gee, S. H., McGee, A. W., Craven, S. E., Santillano, D. R., et al. (1996) Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and a1-syntrophin mediated by PDZ domains. Cell 84, 757-767.

22. Ogura, T., Yokoyama, T., Fujisawa, H., Kurashima, Y., and Esumi, H. (1993) Structural diversity of neuronal nitric oxide synthase mRNA in the nervous system. Biochem. Biophys. Res. Commun. 193, 1014-1022.

23. Hall A. V., Antoniou, H., Wang, Y., Cheung, A. H., Arbus, A. M., Olson, S. L., et al. (1994) Structural organization of the human neuronal nitric oxide synthase gene (NOSI). J. Biol. Chem. 269, 33,082-33,090.

24. Pasternak, G. W. and Standifer, K. M. (1995) Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology. Trends Pharmacol. Sci. 16, 344-350.

25. Pasternak, G. W. and Pan, Y.-X. (2000) Antisense mapping: assessing the functional significance of genes and splice variants, in Antisense Techniques (Phillips, M.I. ed.), Academic, Orlando, FL, pp. 51-60.

26. Kolesnikov, Y., Jain, S., Wilson, R., and Pasternak, G. W. (1998) Lack of morphine and enkephalin tolerance in 129/SvEv mice: evidence for a NMDA receptor defect. J. Pharmacol. Exp. Ther. 284, 455-459.

27. Crain, S. M. and Shen, K. (2000) Enhanced analgesic potency and reduced tolerance of morphine in 129/SvEv mice: evidence for a deficiency in GM1 ganglioside-regulated excitatory opioid receptor functions. Brain Res. 856, 227-235.

Natural Detox

Natural Detox

Are you looking for a full total body detox? If so, then you might want to try a 10 day detox or some refer to it as the 2-week detox. A 10-day detox is a full body detox that usually means taking several different steps to reach your total body transformation. It might involve a change in diet, exercise and more.

Get My Free Ebook


Post a comment